Davita Inc. (NYSE: DVA)

DaVita Inc. is a leading healthcare provider that delivers comprehensive kidney care services to patients worldwide. The company focuses on slowing the progression of chronic kidney disease providing dialysis treatment supporting transplantation and offering integrated care management across the care continuum. DaVita operates dialysis centers provides laboratory services and manages care coordination programs for patients with end stage renal disease and earlier stages of kidney disease. DaVita has been operating for more than twenty five years and has built a platform that integrates clinical care with technology and data analytics. The company’s care model emphasizes patient choice and seeks to deliver preventative services that slow disease progression while preparing patients for transplant when appropriate. DaVita’s workforce includes registered nurses licensed practical nurses patient care technicians social workers dietitians biomedical technicians and administrative staff who work together to deliver high quality dialysis services.

DaVita generates revenue primarily from its U. S. dialysis business which provides outpatient hemodialysis peritoneal dialysis hospital inpatient dialysis and related laboratory services to patients with end stage renal disease. The company also earns revenue from its U. S. integrated kidney care segment through care management contracts with health plans and government programs that include shared savings pay for performance and capitation arrangements. International operations contribute revenue by delivering dialysis and administrative services in outpatient centers located outside the United States. Additional income comes from U. S. other ancillary services such as clinical research transplant software and venture investments that support drug development and innovative care solutions. Revenue is sourced from government programs including Medicare Medicare Advantage Medicaid and the Veterans Administration as well as from commercial insurance payors and direct patient payments. In 2025 the U. S. dialysis segment accounted for approximately eighty six percent of consolidated revenues while the remaining revenue came from integrated kidney care international operations and ancillary services. The company’s laboratory operations provide routine testing for dialysis adequacy mineral metabolism and other health indicators supporting clinical decision making. Management services fees are earned based on a percentage of revenues or cash collections from outpatient dialysis centers in which DaVita holds a noncontrolling interest or provides administrative support. Integrated kidney care contracts often include outcomes based payments that reward improvements in hospitalization rates and mortality risk. International operations generate revenue through fee for service dialysis treatments and through administrative agreements that cover staffing supply chain and quality oversight.

The company operates through the following segments: U. S. dialysis U. S. integrated kidney care international operations and U. S. other ancillary services. These segments are defined by the nature of the services they provide rather than by geography and each contributes differently to the company’s overall revenue profile.

• U. S. dialysis provides dialysis treatments laboratory testing and management services to patients with end stage renal disease across a network of freestanding outpatient dialysis centers hospital based units and home settings. The segment generates revenue from outpatient hemodialysis peritoneal dialysis hospital inpatient dialysis and laboratory services as well as management fees for centers in which DaVita holds a noncontrolling interest or provides administrative support. As of December 31 2025 the U. S. dialysis segment served approximately two hundred thousand five hundred patients across two thousand six hundred fifty seven outpatient dialysis centers located in forty six states and the District of Columbia. The segment also provided hospital inpatient dialysis services to patients in roughly seven hundred forty hospitals throughout the United States. Home based hemodialysis and peritoneal dialysis programs are supported through training equipment and monitoring provided by registered nurses.

• U. S. integrated kidney care delivers care coordination disease management and predictive analytics services to health plan and government program beneficiaries with chronic kidney disease and end stage renal disease. The segment operates under various payment models including shared savings pay for performance and capitation contracts and supports Chronic Special Needs Plans to provide integrated healthcare for eligible patients. As of December 31 2025 the integrated kidney care business managed care for sixty six thousand patients in risk based arrangements and an additional nine thousand four hundred patients in other integrated care arrangements across the United States. The segment works with health plans to design care pathways that include medication management dietary counseling and coordination with transplant centers. Revenue is recognized as services are delivered over contract periods or based on achievement of predefined quality and cost targets.

• International operations own manage or provide administrative services to outpatient dialysis centers in fourteen countries outside the United States serving approximately ninety four thousand five hundred patients. The segment offers hemodialysis and peritoneal dialysis treatments and generates revenue from dialysis services laboratory testing and management fees in markets such as Brazil Colombia Malaysia Poland Chile Germany United Kingdom Ecuador Saudi Arabia Panama Portugal China Japan and Singapore. The international footprint consists of five hundred eighty five outpatient dialysis centers spread across fourteen nations. The largest concentrations are in Brazil with one hundred twenty seven centers Colombia with seventy four centers Malaysia with seventy one centers and Poland with sixty four centers. Smaller operations exist in Chile Germany United Kingdom Ecuador Saudi Arabia Panama Portugal China Japan and Singapore. The segment adapts its treatment offerings to local regulatory requirements while maintaining consistent clinical standards.

• U. S. other ancillary services include clinical research programs transplant software and venture investment activities that support drug development device innovation and new care delivery models. These businesses earn revenue from study sponsorship fees software licensing transactions and strategic investments in companies focused on digital health pharmaceuticals and medical devices for kidney disease patients. The clinical research organization provides services for retrospective and prospective studies supporting drug and device development for kidney disease. The transplant software business known as MedSleuth connects transplant candidates with centers and care teams to improve matching and post transplant outcomes. The venture group seeks early stage investments in digital health pharmaceuticals and medical devices that align with DaVita’s strategy to expand preventive kidney care.

DaVita holds a leading position in the United States dialysis market where it is one of the two largest providers alongside Fresenius Medical Care. The company has been recognized as an industry leader in the Centers for Medicare & Medicaid Services Quality Incentive Program for eleven consecutive years and in the Five Star Quality Rating System for ten consecutive years. DaVita’s competitive advantages stem from its extensive network of dialysis centers its longstanding relationships with nephrologists and hospitals its ability to offer home based and in center dialysis options and its growing integrated kidney care business that leverages value based payment models to improve outcomes and lower total cost of care. The company also benefits from scale in laboratory services management services and ancillary businesses that support its core dialysis operations. Fresenius Medical Care remains DaVita’s primary competitor in the United States dialysis market with both companies together serving a substantial share of the total end stage renal disease patient population. DaVita’s scale enables it to negotiate favorable terms with suppliers and to invest in clinical quality initiatives that have yielded consistent high scores in government quality programs. The company’s integrated kidney care platform differentiates it from pure play dialysis providers by offering care management that addresses the full spectrum of chronic kidney disease. Additionally DaVita’s focus on home based dialysis options aligns with policy incentives that encourage utilization of peritoneal dialysis and home hemodialysis.

DaVita serves patients with end stage renal disease and earlier stages of chronic kidney disease who receive dialysis treatment and care management services. The company’s customers include federal and state government programs such as Medicare Medicare Advantage Medicaid and the Veterans Administration as well as commercial health plans that provide coverage for dialysis services. DaVita also contracts with hospitals that require inpatient dialysis services and with independent laboratories that need specialized testing for kidney disease patients. While the filing does not disclose individual commercial payer names it notes that no single commercial payor accounts for more than ten percent of U. S. dialysis revenue indicating a diversified payer mix. Medicare remains the largest single payer covering approximately seventy three percent of U. S. dialysis patients while Medicare Advantage plans contribute an additional share that varies by region. Medicaid and managed Medicaid programs account for about seven percent of dialysis revenue and the Veterans Administration provides services to a smaller but important segment of patients. Commercial insurance payors collectively represent roughly thirty two percent of U. S. dialysis patient service revenues with no individual commercial payer exceeding ten percent of the segment’s revenue. This diversified payer base reduces reliance on any single source of reimbursement and supports revenue stability across different economic cycles.